TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05062070
Drug: Vehicle Topical Gel
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Study: NCT05052372
Drug: Balversa
Normalized name: Balversa
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
Study: NCT06132191
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04699110
Drug: Adrenaline
Normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
Study: NCT05805800
Drug: 5HT3RA+Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner.
Study: NCT05805800
Drug: 5HT3RA+Olanzapine+Dexamethasone
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered.~Other Names:~Acidocont; Deronil; Dexacortal; Desameton; Fluprednisolone; (11β，16α-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Study: NCT06666413
Drug: Avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion
Study: NCT04226456
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
Study: NCT06477549
Drug: Bendamustine Hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
Study: NCT06477549
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days -7 through -2: ruxolitinib 5 mg tid per os
Study: NCT05143229
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI3K inhibitor
Study: NCT05143229
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
Study: NCT00309673
Drug: lidocaine / Prilocaine
Normalized name: lidocaine / prilocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04845919
Drug: 5-Aminolevulinic Acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System.
Study: NCT06150716
Drug: ION356
Normalized name: ION356
DrugBank: ION356 (DB19389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as intrathecal (IT) injection.
Study: NCT06685705
Drug: Magnesium Sulfate and Bupivacaine 0.125%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.
Study: NCT06685705
Drug: bupivacaine and Neostigmine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally
Study: NCT06685705
Drug: fentanyl and bupivacaine
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
Study: NCT05445232
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT05445232
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05922761
Drug: Belumosudil
Normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kinase inhibitor, tablet taken orally
Study: NCT05922761
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Via inhalation by metered-dose inhaler.
Study: NCT05922761
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid, taken orally
Study: NCT05922761
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukotriene Receptor Antagonist, taken orally
Study: NCT05993897
Drug: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Normalized name: CO
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of Dapagliflozin orally once daily
Study: NCT05993897
Drug: Rhythm control and anticoagulation
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females.
Study: NCT06665048
Drug: Oxycodone HCl
Normalized name: oxycodone HCl
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
Study: NCT06066996
Drug: Transdermal Nicotine Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Nicotine Patch
Study: NCT06066996
Drug: Placebo Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Patch with No Nicotine
Study: NCT05419180
Drug: Stiripentol
Normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
Study: NCT06457074
Drug: Finerenone Oral Tablet
Normalized name: finerenone Oral Tablet
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
Study: NCT05267392
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
Study: NCT06137742
Drug: PF-07868489
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Treatment
Study: NCT04517227
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
Study: NCT06366347
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK inhibitor, tablet taken orally per protocol.
Study: NCT06366347
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitor, tablet taken orally per protocol.
Study: NCT06366347
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
Study: NCT05590416
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
Study: NCT04243941
Drug: 68Ga-HBED-CC-PSMA
Normalized name: (68Ga)Psma-hbed-CC
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
Study: NCT04429555
Drug: Ibudilast
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 50 mg (5 x 10 mg capsules) twice daily for 7 days
Study: NCT04786730
Drug: Centanafadine
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
Study: NCT05004350
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral hard capsule
Study: NCT05004350
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous infusion
Study: NCT04979780
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Retrospective cohort analysis using US Optum De-Identified EHR data.
Study: NCT00002251
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05845762
Drug: Obinutuzumab Injection
Normalized name: obinutuzumab Injection
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000mg intravenous injection
Study: NCT06181734
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhibitor of mutant IDH1
Study: NCT06519357
Drug: Lamivudine 300 MG
Normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants receive 300 mg of Lamivudine daily for 24 weeks
Study: NCT06239532
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
Study: NCT06239532
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
Study: NCT06289478
Drug: Topical tranexamic acid administration
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid will be topically administered in intervention groups
Study: NCT05631093
Drug: ART
Normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care ART, per approved product list, taken orally
Study: NCT05398289
Drug: 4-week duration of antibiotic therapy
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
Study: NCT05398289
Drug: 6-week duration of antibiotic therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
Study: NCT05872256
Drug: 0.045% Tazarotene/0.01% Halobetasol Lotion
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved drug for psoriasis treatment
Study: NCT06083961
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial alirocumab, single dose of 300mg, subcutaneous injection
Study: NCT06532812
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT06532812
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT06532812
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study: NCT06532812
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT05878184
Drug: SC291
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC291 is an allogeneic CAR-T cell therapy
Study: NCT00000818
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05027906
Drug: AT-1501
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigative Arm
Study: NCT05535075
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin treatment
Study: NCT06253637
Drug: Daratumumab plus chemotherapy according to the national treatment program
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab is a human IgG1қ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein which is expressed in several hematological malignancies including multiple myeloma (MM) and ALL. Daratumumab induces lysis of CD38-expressing tumor cells by several mechanisms. Intravenous daratumumab has been approved first as a single agent and then in combinations in the MM setting and in AL amyloidosis.~The activity of daratumumab in ALL is being explored in the DELPHINUS trial, in which the drug was combined with chemotherapy in pediatric and young adult patients with relapsed/refractory T-cell ALL or lymphoblastic lymphoma (LL).~In the present trial, daratumumab will be administered to adult Very high risk T-lineage ALL weekly in induction and early consolidation (C1-C2), and the first day of each of the following intensive cycles up to C8.
Study: NCT06574698
Drug: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Normalized name: Extract of the Sterile Caules of Equisetum Arvense
DrugBank: Equisetum arvense top (DB14349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Study: NCT06457191
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
Study: NCT04878055
Drug: Reparixin
Normalized name: Reparixin
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
Study: NCT04990388
Drug: H2 Blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will receive oral premedication prior to infusion
Study: NCT04990388
Drug: H1 Blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will receive oral premedication prior to infusion
Study: NCT05590559
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opiates
Study: NCT04320693
Drug: IMMU-132
Normalized name: IMMU-114
DrugBank: IMMU-114 (DB18458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
Study: NCT05113771
Drug: Liafensine
Normalized name: Liafensine
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liafensine
Study: NCT06665412
Drug: Radotinib Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Radotinib (DB12323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID, every day up to 12months
Study: NCT06682195
Drug: Neoadjuvant chemotherapy combined with Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment.
Study: NCT04750967
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
Study: NCT04750967
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline 25 mg daily
Study: NCT06362980
Drug: BPI-1178
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 or 300 mg, oral, QD
Study: NCT06362980
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg, oral, QD
Study: NCT04726618
Drug: Hyperpolarized 129-xenon gas and Perfluoropropane gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane).
Study: NCT05799612
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05799612
Drug: PEGYLATED-INTERFERON ALPHA-2A
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05799612
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT04286789
Drug: Low dose ORTD-1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
Study: NCT04286789
Drug: Low dose vehicle control
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
Study: NCT04286789
Drug: High dose ORTD-1
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
Study: NCT04286789
Drug: High dose vehicle control
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.